Form 8-K - Current report:
SEC Accession No. 0000950170-25-030396
Filing Date
2025-03-03
Accepted
2025-03-03 07:06:12
Documents
13
Period of Report
2025-03-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nmra-20250303.htm   iXBRL 8-K 43805
2 EX-99.1 nmra-ex99_1.htm EX-99.1 169292
3 GRAPHIC img49001591_0.jpg GRAPHIC 27072
  Complete submission text file 0000950170-25-030396.txt   376486

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nmra-20250303.xsd EX-101.SCH 25038
15 EXTRACTED XBRL INSTANCE DOCUMENT nmra-20250303_htm.xml XML 4763
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 25693740
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)